Ipsen’s Pav Rishiraj joins David Kološić to discuss why pharmacovigilance is the nucleus of the industry, and how moving from reactive to predictive safety will improve benefit-risk analysis and establish safety as a strategic enabler for the entire business.

In this episode of Safety [R]Evolution, Andrew Rut joins David Kološić to discuss shifting PV from reactive data collection and reporting to a predictive, digital-first model that carefully considers the patient experience, integrates AI and automation, and positions safety as a competitive advantage.

UCB’s Adrian Maynier and Veeva’s Mayuran Croos join David Kološić to discuss how to approach a “big bang” consolidation of 17 siloed safety systems into one unified platform for case processing, reporting, signal detection, and content.

David Kološić speaks with Veeva’s Marius Mortensen about the long-term vision for Veeva Safety; the benefits of starting with a trusted, validated cloud platform; and how a platform approach enables connected data and processes, advanced automation, and AI. 

Biomapas’ Martijn van de Leur and Olga Asimaki join David Kološić to discuss the importance of CRO-sponsor partnerships in pharmacovigilance. They also talk about the need for simplification and standardization, progress on automation and AI, and how QPPV’s are adapting to shifting technology. 

In Episode 2, Eliquent Life Sciences’ Emma-Jane Brookes and Jamie Portnoff speak with David Kološić about simplifying and standardizing PV technology, harmonizing processes across teams and regions, and driving PV transformation through effective change management. Disclaimer: The views expressed are those of the individuals and do not represent Eliquent Life Sciences. 

In our launch episode, David Kološić talks with Sandoz’s Aniket Agarwal about how the right data and technology foundation improves speed and operational efficiency for pharmacovigilance teams. We also discuss the benefits and challenges of automation and AI, and where rapidly evolving technologies will take safety in the future. Disclaimer: The views expressed are those of the individual and do not represent Sandoz.